This post was originally published on Medscape
You will shortly be re-directed to the publisher's website
Novo Nordisk will begin a late-stage trial of its experimental next-generation obesity drug CagriSema on Feb. 10 to test its long-term efficacy, according to a…
Reuters Health Information